Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

599 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle.
Schernthaner G, Wanner C, Jurišić-Eržen D, Guja C, Gumprecht J, Jarek-Martynowa IR, Karasik A, Lalić N, Mankovsky BN, Prázný M, Tankova T, Tsur A, Wascher TC, Wittmann I. Schernthaner G, et al. Diabetes Res Clin Pract. 2019 Jul;153:30-40. doi: 10.1016/j.diabres.2019.05.013. Epub 2019 May 20. Diabetes Res Clin Pract. 2019. PMID: 31121272 Free article.
Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG).
Schernthaner G, Lehmann R, Prázný M, Czupryniak L, Ducena K, Fasching P, Janež A, Karasik A, Kempler P, Martinka E, Shestakova MV, Duvnjak LS, Tankova T. Schernthaner G, et al. Cardiovasc Diabetol. 2017 Oct 23;16(1):137. doi: 10.1186/s12933-017-0622-7. Cardiovasc Diabetol. 2017. PMID: 29061170 Free PMC article. Review.
SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class.
Schernthaner G, Drexel H, Moshkovich E, Zilaitiene B, Martinka E, Czupryniak L, Várkonyi T, Janež A, Ducena K, Lalić K, Tankova T, Prázný M, Smirčić Duvnjak L, Sukhareva O, Sourij H. Schernthaner G, et al. BMC Endocr Disord. 2019 Jun 17;19(1):64. doi: 10.1186/s12902-019-0387-y. BMC Endocr Disord. 2019. PMID: 31208401 Free PMC article.
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, Janež A, Kempler P, Konrāde I, Lalić NM, Mankovsky B, Martinka E, Rahelić D, Serafinceanu C, Škrha J, Tankova T, Visockienė Ž. Schernthaner G, et al. Cardiovasc Diabetol. 2020 Oct 23;19(1):185. doi: 10.1186/s12933-020-01154-w. Cardiovasc Diabetol. 2020. PMID: 33097060 Free PMC article. Review.
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs.
Schernthaner G, Karasik A, Abraitienė A, Ametov AS, Gaàl Z, Gumprecht J, Janež A, Kaser S, Lalić K, Mankovsky BN, Moshkovich E, Past M, Prázný M, Radulian G, Smirčić Duvnjak L, Tkáč I, Trušinskis K. Schernthaner G, et al. Cardiovasc Diabetol. 2019 Aug 31;18(1):115. doi: 10.1186/s12933-019-0920-3. Cardiovasc Diabetol. 2019. PMID: 31472683 Free PMC article.
Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
Schernthaner G, Lotan C, Baltadzhieva-Trendafilova E, Ceponis J, Clodi M, Ducena K, Goncalvesova E, Guja C, Honka M, Janež A, Lalić N, Lehmann R, Nyolczas N, Pauklin P, Rynkiewicz A, Sergienko I, Duvnjak LS. Schernthaner G, et al. Cardiovasc Diabetol. 2018 Nov 21;17(1):145. doi: 10.1186/s12933-018-0788-7. Cardiovasc Diabetol. 2018. PMID: 30463621 Free PMC article.
The right place for metformin today.
Schernthaner G, Schernthaner GH. Schernthaner G, et al. Among authors: schernthaner gh. Diabetes Res Clin Pract. 2020 Jan;159:107946. doi: 10.1016/j.diabres.2019.107946. Epub 2019 Nov 26. Diabetes Res Clin Pract. 2020. PMID: 31778746 Review.
599 results